Pre-made Fibatuzumab benchmark antibody ( Whole mAb, anti-EPHA3 therapeutic antibody, Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fibatuzumab is a humanised monoclonal antibody directed against the ephrin receptor A3 (EPHA3) , which is a receptor tyrosine kinase implicated in mediating nervous system development .

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-211-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Fibatuzumab biosimilar, Whole mAb, Anti-EPHA3 Antibody: Anti-EK4/ETK/ETK1/HEK/HEK4/TYRO4 therapeutic antibody
INN Name	Fibatuzumab
Target	EPHA3
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2017
Companies	Ludwig Institute for Cancer Research;Humanigen;Olivia Newton-John Cancer Research Institute
Conditions Approved	na
Conditions Active	Acute myeloid leukaemia;Myelodysplastic syndromes;Myelofibrosis;Glioblastoma
Conditions Discontinued	na
Development Tech	POTELLIGENT Technology;Humaneering Technology